A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options (CHANGE)

A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance Nerve Graft Evaluating Recovery Outcomes of Nerve Repair in the Hand. (CHANGE)

This study is a comparison of sensory recovery outcomes following the use of AVANCE Nerve Graft or hollow tube conduit for peripheral nerve gap repairs in the hand.

Study Overview

• Status: Terminated
• Conditions: Traumatic Nerve Injury
• Intervention / Treatment: Other: Processed Human Nerve Tissue; Device: Hollow tube nerve conduit, synthetic or biosynthetic

Detailed Description

The CHANGE study is a post-marketing study designed as a prospective, single-blind, randomized, two phase study comparing clinical outcomes of AVANCE Nerve Graft to hollow tube conduits. The first phase (pilot phase) assesses projected differences expected between two treatment groups. The second phase of the study provides comparison data between the two treatment groups.

AVANCE Nerve Graft is current regulated in the United States as a 361 HCT/P Tissue for transplantation; not a Drug, Biologic, or Medical Device. Hollow tube conduits are currently regulated in the United States as medical devices.

• Study Type: Interventional
• Enrollment (Actual): 23
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Georgia
    • Atlanta, Georgia, United States, 30309
      • Georgia Hand, Shoulder and Elbow
  • Indiana
    • Indianapolis, Indiana, United States, 46260
      • Indiana Hand Center
  • Kentucky
    • Lexington, Kentucky, United States, 40536
      • University of Kentucky
  • Maryland
    • Baltimore, Maryland, United States, 21218
      • Curtis National Hand Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Require primary or secondary nerve injury repair with Hollow Nerve Conduit or AVANCE™ in at least 1 digital nerve;
• Undergo End to End nerve to nerve graft coaptation on both the proximal and distal portion of the nerve gap in the AVANCE™ group or nerve entubulation in the Hollow Nerve Conduit group;
• Be willing to comply with all aspects of the treatment and evaluation schedule over a 12 Month duration; and
• Sign and date an IRB-approved written informed consent prior to initiation of any study procedures, including screening procedures.

Exclusion Criteria:

• Nerve gaps of < 5 mm or > 20 mm;
• Estimated distance of regeneration of >125 mm (distance from injury site to sensory target)
• Nerve crush or avulsion injuries;
• Incomplete nerve transections;
• Injury requiring replantation of target digit;
• Contralateral digital injuries corresponding to the target digit;
• Nerve injuries in the affected limb proximal to the crease of the wrist;
• End to side nerve repair;
• Injuries with significant vascular damage which may impair adequate perfusion of the target limb;
• Subjects who are undergoing treatment with chemotherapy, radiation therapy, or other know treatment which affects the growth of neural and/or vascular system;
• Use of bovine collagen based hollow nerve conduit in a subject with known or suspected bovine sensitivity;
• Subjects age ≤18 years or ≥70 years;
• History neuropathy, diabetic or any other known neuropathy;
• Secondary nerve repair >12 weeks post initial injury;
• Currently enrolled in another investigational study;
• Expected use of medications during the study that are known to cause peripheral neuropathy;
• History or Reynaud's or other disorder known to compromise circulation or sensation in the upper extremity; and
• Any subject who at the discretion of the Investigator is not suitable for inclusion in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Avance Nerve Graft; Commercially available Avance Nerve Graft for repair of nerve gap	Other: Processed Human Nerve Tissue; Implantation of appropriate length of processed human nerve tissue at time of surgery.; Other Names: Avance Nerve Graft
Active Comparator: Hollow Tube Conduit; Commercially available hollow tube conduit for repair of nerve gap.	Device: Hollow tube nerve conduit, synthetic or biosynthetic; Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex); Other Names: Neurotube; NeuroLac; NeuraGen; NeuroMatrix; NeuroFlex

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recovery of Static 2-point Discrimination in the Affected Digit	Mean change in static 2-Point Discrimination between baseline and 12 months	12 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Moving 2-point Discrimination	Percent Change from Baseline of Moving 2-Point Discriminations at Month 12	12 months
Semmes-Weinstein Monofilament Assessment	Percent Change from Baseline of Semmes-Weinstein Monofilament Assessment at Month 12	12 months
12-month DASH Core Module Scores	Summary of Disability of the Arm, Shoulder, and Hand (DASH) scores (Core Module) at Month 12 The Disabilities of the Arm, Shoulder and Hand (DASH) core module questionnaire is a 30-item questionnaire includes 21 physical function items, 6 symptom items, and 3 social/role function items. It is a patient reported questionnaire used to assess physical function and severity of symptoms in patients with musculoskeletal disorders of the upper limb. Each of the items in the DASH use a 5-point Likert scale to assess the corresponding severity or functional parameter. The outcome measure is scored based on the formula ([sum of n responses)/ - 30 (minimum score]/1.2 (range of scores ÷100), where n represents the number of completed items. Computed scores range from 0 (no disability) to 100 (most severe disability).	12 months
12-month DASH (Work Module) Scores	Summary of Disability of the Arm, Shoulder, and Hand (DASH) scores (Work Module) at Month 12 The Disabilities of the Arm, Shoulder and Hand (DASH) Work Module questionnaire is a 4-item questionnaire used to identify the job-specific difficulties that workers might experience but which may not affect their activities of daily living. It is a patient reported questionnaire used to assess the impact that musculoskeletal disorders of the upper limb have on a patient's ability to perform work-related tasks. Each of the items in the DASH Work Module use a 5-point Likert scale to assess the corresponding severity or functional parameter. The outcome measure is scored based on the formula ([sum of n responses)/ - 4 (minimum score]/0.16 (range of scores ÷100), where n represents the number of completed items. Computed scores range from 0 (no difficulty) to 100 (most severe difficulty).	12 month
12- Month DASH (Sports/Performing Arts Module)	Summary of Disability of the Arm, Shoulder, and Hand (DASH) scores (Sports/Performing Arts Module) at month 12 The Disabilities of the Arm, Shoulder and Hand (DASH) Sports/Performing Arts Module questionnaire is a 4-item questionnaire used to identify the specific difficulties that professional athletes/performing artists might experience but which may not affect their activities of daily living. It is a patient reported questionnaire used to assess the impact that musculoskeletal disorders of the upper limb have on a patient's ability to perform sports or play a musical instrument. Each of the items in the DASH use a 5-point Likert scale to assess the corresponding severity or functional parameter. The outcome measure is scored based on the formula ([sum of n responses)/ - 4 (minimum score]/0.16 (range of scores ÷100), where n represents the number of completed items. Computed scores range from 0 (no difficulty) to 100 (most severe difficulty).	12 months
Pain at 12-months	Summary of Pain Assessment using Visual Analogue Scale (VAS) at Month 12 The Visual Analog Scale (VAS) For Pain is a patient reported outcomes scale whereby the patient indicates his/her current pain level by making a mark on a continuous horizontal 10 centimeter (100 millimeter) line. The distance from the 0 millimeter to the patient's mark corresponds to the amount of pain the subject is currently experiencing. VAS for Pain data are recorded as the number of millimeters from the left of the line to the patients mark across the range of 0-100 millimeters, with 0 millimeter representing no pain and 100 millimeters representing "the worst pain imaginable".	12-months
Thermal Discretion at 12-months	Summary of Thermal Discretion at Month 12 as determined by the Investigator. Thermal discretion was assessed by applying a hot and/or cold object to the patient's affected digit. Thermal discretion was reported as either present ("Yes") or not present ("No").	12-month
Protective Sensation Present at 12-months	Summary of Protective Sensation by Month 12 Semmes-Weinstein Monofilament (SWMF) assessment of protective sensation. The gauge of the monofilaments range from 2.83 (normal) to 6.65 (deep pressure sensation only). Protective Sensation Present (SWMF score of 3.61 or better), Protective Sensation Diminished (SWMF score of 4.31-3.84), Protective Sensation Absent (SWMF score of 4.56 or greater).	12 months
Functional Recovery Classification (Medical Research Council Evaluation of Sensory Function) at 12-months	Summary of Functional Recovery Classification (Medical Research Council Evaluation of Sensory Function) at 12-months Patients were assessed for functional recovery of sensation on a scale from S0 to S4 with S0 representing absence of sensibility, S1 representing recovery of deep cutaneous pain sensibility, S2 representing the return of some degree of superficial cutaneous pain and tactile sensibility, S3 representing return of superficial cutaneous pain and tactile sensibility, S3+ representing return of sensibility as in S3 and some recovery of 2-point discrimination (a 2-PD score between 7-15mm), and S4 representing complete recovery of normal sensation as assessed by 2-point discrimination (score between 2-6mm).	12 months

Collaborators and Investigators

• Sponsor: Axogen Corporation
• Investigators: Study Director: Erick W DeVinney, Axogen Corporation

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2009
• Primary Completion (Actual): December 1, 2014
• Study Completion (Actual): December 1, 2014

Study Registration Dates

• First Submitted: July 17, 2009
• First Submitted That Met QC Criteria: July 28, 2009
• First Posted (Estimate): July 29, 2009

Study Record Updates

• Last Update Posted (Actual): December 1, 2020
• Last Update Submitted That Met QC Criteria: November 6, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Keywords: Conduit; Peripheral Nerve Repair; AVANCE; Neuroma Resection; Nerve Gap Repair; Digital Nerve Repair; Nerve Graft; Nerve Allograft
• Other Study ID Numbers: ANG-CP-004

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No
• IPD Plan Description: IPD will not be released to other researchers.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes